News | February 7, 2019

HARPOON THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Harpoon Therapeutics, Inc. (“Harpoon”), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today the...

News | January 2, 2019

HARPOON THERAPEUTICS ANNOUNCES PRELIMINARY SAFETY AND PHARMACOLOGY DATA FROM ITS HPN424 PHASE 1 TRIAL IN PROSTATE CANCER Initial data shows HPN424 serum exposure supports weekly dosing Changes in blood-derived tumor cell and serum biomarkers consistent with T cell...
felis Lorem leo. quis, libero dapibus Nullam justo